Promises and controversies in the management of low-grade glioma
Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why?
The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer
Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience
Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
Continuously elevated cardiac troponin I in two patients with multiple myeloma and fatal cardiac amyloidosis
Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment
High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma with or without antiretroviral therapy during antineoplastic agents
Role and limits of salvage chemotherapy in breast cancer patients treated with high-dose chemotherapy
Can the ISO9000 quality assessment be applied to the practice of medical oncology?
Cancer Cell Signaling: Methods and Protocols